期刊
GENES CHROMOSOMES & CANCER
卷 51, 期 1, 页码 54-65出版社
WILEY-BLACKWELL
DOI: 10.1002/gcc.20930
关键词
-
资金
- AACR-SU2C Innovative Research [SU2C-AACR-IR60109]
- VICC Cancer Center Core [P30-CA68485]
- German Ministry of Science and Education (BMBF) [01GS08100]
- Max Planck Society [M.I.F.A. NEUR8061]
- Deutsche Forschungsgemeinschaft (DFG) [SFB832]
- Deutsche Krebshilfe [107954]
- Fritz-Thyssen-Stiftung [10.08.2.175]
- Sequenom
- Sanofi-Aventis
- Merck
- Roche
- Infinity
- Boehringer-Ingelheim
- Johnson Johnson
- Atlas-Biolabs
- Novartis
- AstraZeneca
- NCI Cancer Center [P30-CA008748]
Gene fusions involving the catalytic domain of tyrosine kinases (TKs) are found in a variety of hematological and solid tumor malignancies. Clinically, TK fusions have emerged as prime targets for therapy with small molecule kinase inhibitors. Unfortunately, identification of TK fusions has been hampered by experimental limitations. Here, we developed version 2.0 of a genomically based systematic kinase fusion screen and used it to detect a novel imatinib-sensitive C6orf204-PDGFRB fusion in a patient with precursor T lymphoblastic lymphoma (T-ALL) and an associated myeloproliferative neoplasm with eosinophilia. These data validate the ability of this targeted capture-sequencing approach to detect TK fusion events in small amounts of DNA extracted directly from patient samples. (C) 2011 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据